-
Luye Pharma and ESTEVE reach an agreement to commercialize a new Alzheimer's disease drug in Spain
Time of Update: 2021-10-01
Liss' Mindo Day transdermal patch is used to treat mild and moderate dementia related to Alzheimer's disease.
It is independently developed by Luye Pharmaceuticals and has recently been approved for marketing in Spain .
-
Another insulin will be on the market, intensifying market competition is inevitable
Time of Update: 2021-10-01
Recently, Hisun Pharmaceuticals issued an announcement stating that it received the "Drug Registration Certificate" for insulin aspart injection approved and issued by the National Medical Products Administration on September 13, 2021.
-
How should the relevant companies respond to the long-term trend of rising prices of Chinese medicinal materials?
Time of Update: 2021-10-01
At the same time, a group of companies have also disclosed risk warnings due to the price increase of Chinese medicinal materials: due to the scarcity of wild resources of Chinese medicinal materials, artificial planting is affected by factors such as the climate environment and planting area, the company may face the risk of insufficient supply of raw materials.
-
Many provinces and cities have issued documents, and the transfer of local medical insurance supplements has entered a critical period
Time of Update: 2021-10-01
Among them, according to the notice issued by the Xinjiang Medical Insurance Bureau, it is clear that starting from January 1, 2022, the "Xinjiang Uygur Autonomous Region and Xinjiang Production and Construction Corps Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog" will be added to the non-ethnic medicines All 305 varieties were transferred out of the scope of medical insurance payment .
-
The biological products sector performed outstanding performance in the first half of the year. Revenue increased by nearly 36% year-on-year
Time of Update: 2021-10-01
. Watson Biological released the 2021 semi-annual report on the evening of August 27, stating that the company achieved double growth in revenue and profits in the first half of the year, of which operating income was 1.
-
Documents issued in many provinces, the management of traditional Chinese medicine formula particles will continue to be stricter
Time of Update: 2021-10-01
It is worth noting that with the continuous expansion of the TCM formula granule market, in order to strengthen the management of TCM formula granules, standardize the production of TCM formula granules, and guide the healthy development of the industry, the State Food and Drug Administration issued the "Regarding the End of TCM Formula Granules" in February this year.
-
BeiGene receives positive opinions from the European Medicines Agency's Committee for Human Medicines (CHMP) on the treatment of adult patients with Fahrenheit's macroglobulinemia
Time of Update: 2021-10-01
Beijing, China, Basel, Switzerland and Cambridge, Massachusetts, September 17, 2021/PRNewswire/ - BeiGene (Nasdaq: BGNE; Hong Kong Stock Exchange: 06160) today announced the European Medicines Management The Committee on Medicines for Human Use (CHMP) of the Agency (EMA) recommends approval of Baiyueze® (Zebutinib) for adult patients with Waldenstrom's macroglobulinemia (WM) who have previously received at least one treatment, or as an unsuitable chemical First-line treatment options for immunotherapy of WM patients .
-
Fuhong Henlius submits an application for new indications of anti-PD-1 monoclonal antibody
Time of Update: 2021-10-01
Text|Pharmaceutical Mission HillsOn September 16, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that Fuhong Henlius had submitted a new indication application for the anti-PD-1 monoclonal antibody slulimumab injection and was accepted .
-
Keji Pharmaceutical's CT041 CAR-T treatment of digestive system tumors and advanced gastric cancer efficacy data is eye-catching
Time of Update: 2021-10-01
Solid tumor CAR-T debuts with ESMO clinical treatment data for advanced gastric cancerThe study presented in the 2021 ESMO oral report is a clinical trial initiated by a multi-center, open-label Phase I investigator in China.
-
ESMO 2021 CStone Pharmaceuticals announces the clinical data of the Chinese registration bridging study of Afnib in patients with relapsed/refractory acute myeloid leukemia who are susceptible to IDH1 mutations
Time of Update: 2021-10-01
Efficacy data show that Avonib has excellent clinical efficacy in the treatment of adult Chinese patients with relapsed or refractory acute myeloid leukemia (R/R AML) who are susceptible to IDH1 mutat
-
Domestic pharmaceutical companies are accelerating the improvement of innovation capabilities through "bringing in"
Time of Update: 2021-10-01
According to the terms of the agreement, Genting Shining will pay SinoVision and China Antibodies an advance payment of US$12 million and a total of US$549 million in future development, registration and commercialization milestone payments, as well as high single-digit global net sales.
-
With favorable policies, the health of the pharmaceutical retail industry will continue to improve
Time of Update: 2021-10-01
However, it should be noted that under the background of policy guidance, health industry upgrades, and changes in consumer demand that promote the acceleration of the development of the pharmaceutical retail industry, this market is actually facing many new challenges .
-
In the first eight months, domestic manufacturing investment increased by 15.7% year-on-year, and the pharmaceutical industry actively embraced opportunities
Time of Update: 2021-10-01
From the perspective of national and local policies, intelligence, digitization, and greenization will be the new requirements for the high-quality development of the entire manufacturing industry, and the same is true in the pharmaceutical equipment industry .
-
BeiGene announced to be included in the FTSE Russell Index
Time of Update: 2021-10-01
Cambridge, MA, USA and Beijing, China, September 20, 2021/PRNewswire/ - BeiGene (NASDAQ: BGNE; HKEX: 06160) is a science-based global biotechnology company focused on development, innovation, and affordable The drug is designed to improve the effectiveness of treatment and increase the accessibility of drugs for patients around the world .
-
The drop was as high as 99.1%!
Time of Update: 2021-10-01
" According to the review of the publicity documents, 64 pharmaceutical companies voluntarily applied for price reductions this time, involving 110 drugs, including bevacizumab injection, human interferon α1b for injection, and recombinant human Erythropoietin injection (CHO cells), Aesculus esculentus dispersible tablets, Gastrodin injection, Asarone injection, Cinacalcet hydrochloride tablets, Dexmedetomidine hydrochloride injection, Levofloxacin tablets, Chuangzhi capsules, compound DDB sheet, compound liquorice tablets and the like .
-
The remission rate is 17.3% higher than that of monotherapy!
Time of Update: 2021-10-01
New data shows that the combination of KRAS G12C inhibitor Lumakras (sotorasib) and Amgen Anti-EGFR monoclonal antibody Vectibix (panitumumab) has encouraging efficacy and safety .
This dose exploration and dose expansion cohort study enrolled 31 patients with KRAS G12C mutation metastatic CRC who had received extensive pretreatment (median 2 front-line therapy; range 1-10) .
-
Special rectification of online pharmacies is coming
Time of Update: 2021-10-01
The briefing stated that since the launch of the special action, all units in the city have arranged 1,059 drug online sales entities, and have inspected 19 wholesale companies, 820 retail companies and 1 Internet drug trading third-party platform for drug network operations .
-
20 billion USD BTK inhibitor competition is intensifying. Who is the real "king"?
Time of Update: 2021-10-01
Figure: Zebutinib and Ibrutinib in the treatment of WM head-to-head trialData source: BeiGeneOn December 28, 2020, Baiyueze's two conditional approved indications for MCL and CLL/SLL were included in the National Medical Insurance Catalog, which will take effect on March 1, 2021 .
-
Traditional Chinese medicine cross-border "breaking the circle" out of the sense of youthful fashion
Time of Update: 2021-10-01
At the same time, it promotes cross-border cooperation between its pharmaceutical companies and other industries to form a consumer fashion Traditional Chinese medicine has become "trend", such as co-launching health-preserving oatmeal with Quaker, a subsidiary of Pepsi,; Wanglaoji, a subsidiary of PepsiCo, has innovated and changed, and has successively launched new herbal tea products to meet consumers' personalized and diversified health needs.
-
Focusing on the future plans of the pharmaceutical equipment giants, the field of biomedicine will become a "sweet potato"?
Time of Update: 2021-10-01
It is foreseeable that in the process of increasing investment in the industry, upstream biopharmaceutical-related equipment will also usher in a new round of opportunities, and demand will continue to grow.
